Chronic conventional disease-modifying anti-rheumatic drugs masking severe SARS-CoV-2 manifestations in an elderly rheumatic patient

J Infect. 2020 Dec;81(6):979-997. doi: 10.1016/j.jinf.2020.05.043. Epub 2020 May 29.

Authors

Caterina Sagnelli¹, Valeria Gentile¹, Rosella Tirri², Margherita Macera¹, Salvatore Cappabianca², Francesco Ciccia², Nicola Coppola¹; Vanvitelli COVID-19 group¹

Affiliations

¹ Department of Mental Health and Public Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.
² Department of Scienze Mediche Traslazionali, University of Campania "Luigi Vanvitelli", Naples, Italy.

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adrenal Cortex Hormones / therapeutic use
Aged, 80 and over
Antibodies, Monoclonal, Humanized / therapeutic use
Antirheumatic Agents / adverse effects
Antirheumatic Agents / therapeutic use*
Arthritis, Rheumatoid / complications
Arthritis, Rheumatoid / drug therapy*
COVID-19 / complications*
COVID-19 Drug Treatment
Female
Humans
Hypertension / complications
Methylprednisolone / therapeutic use
Pneumonia, Viral / complications
Pneumonia, Viral / diagnostic imaging
Pneumonia, Viral / drug therapy
Rheumatic Diseases / complications
Rheumatic Diseases / drug therapy
SARS-CoV-2
Severity of Illness Index
Tomography, X-Ray Computed
Treatment Outcome

Substances

Adrenal Cortex Hormones
Antibodies, Monoclonal, Humanized
Antirheumatic Agents
tocilizumab
Methylprednisolone